Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The National Institute Of Technology maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 1 distinct examiner working within 1 distinct art unit. This structure indicates that the institute's current prosecution efforts are centralized, with all active matters subject to the same examination standards and technical oversight.
DICKINSON, PAUL W serves as the busiest examiner, managing 2 busiest examiner pending office actions. Since this count matches the total of 2 pending office actions, this single examiner oversees the entire active portfolio. This concentration provides an opportunity for the applicant to develop a consistent rapport and negotiation style with DICKINSON, PAUL W across multiple filings.
The presence of only 1 distinct art unit suggests that the technical subject matter is closely related, falling under a unified set of examination guidelines. Focusing resources on the specific requirements of the 1 distinct examiner is essential for resolving the active cases efficiently. This centralized workload reduces the complexity often associated with managing diverse examiner perspectives across different sectors of the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 2 | 63.1% | +9.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17962198 | LIGHT-EMITTING NANOPARTICLES, CELL DETECTION METHOD USING SAME, ANIMAL TREATMENT METHOD, MEDICAL DEVICE, CELL VISUALIZATION METHOD, AND METHOD FOR REDUCING INJURY TO CELL | DICKINSON, PAUL W | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17962198 | LIGHT-EMITTING NANOPARTICLES, CELL DETECTION METHOD USING SAME, ANIMAL TREATMENT METHOD, MEDICAL DEVICE, CELL VISUALIZATION METHOD, AND METHOD FOR REDUCING INJURY TO CELL | DICKINSON, PAUL W | 1618 | §102§103§112 | Non-Final OA | — | Pending | Oct 07, 2022 |
| 16089758 | LIGHT-EMITTING NANOPARTICLES, CELL DETECTION METHOD USING SAME, ANIMAL TREATMENT METHOD, MEDICAL DEVICE, CELL VISUALIZATION METHOD, AND METHOD FOR REDUCING INJURY TO CELL | DICKINSON, PAUL W | 1618 | §103 | Non-Final OA | 28d | Pending | Sep 28, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial